This inventor holds 30 USPTO granted patents and 23 published patent applications, plus 7 CIPO patents and 10 EPO patents, primarily in Antibody Drug Conjugates. Top assignees: Syngenta Participations Ag, Sorrento Therapeutics, Inc., Concortis Biosystems, Corp.. Active years: 2003-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Johnston, IA (US) (2003 - 2005)
- Chapel Hill, NC (US) (2005 - 2010)
- Durham, NC (US) (2009 - 2012)
- Research Triangle Park, NC (US) (2009 - 2013)
- San Diego, CA (US) (2006 - 2024)
Company Filing History:
7 out of 1,779 
6 out of 114 
4 out of 4 
Years Active: 2003-2026
Areas of Expertise:
Title: Innovations in Drug-Conjugates: The Contributions of Tong Zhu
Introduction: Tong Zhu is a prominent inventor based in San Diego, CA, who has made significant strides in the field of drug conjugates. With an impressive portfolio of 28 patents, Zhu's contributions to pharmaceutical science have paved the way for advanced treatment options.
Latest Patents: One of Zhu's latest patents involves drug-conjugates, conjugation methods, and their uses. This patent describes an active agent-conjugate along with methods for its preparation and various applications. Another notable patent focuses on drug-conjugates with a targeting molecule and two distinct drugs, showcasing an improved antibody-drug conjugate (ADC) composition. This innovative design involves attaching a first drug conjugate to a dual cysteine residue on a targeting protein, while a second drug conjugate with a different payload is attached to a lysine residue, enhancing the therapeutic efficacy of the treatment.
Career Highlights: Throughout his career, Tong Zhu has collaborated with leading companies in the pharmaceutical industry, such as Syngenta Participations AG and Sorrento Therapeutics, Inc. His work has significantly influenced the development of targeted therapies and drug delivery systems.
Collaborations: Zhu has worked alongside esteemed colleagues, including Zhenwei Miao and Yufeng Hong. Together, they have driven forward research and innovation in drug conjugate technologies.
Conclusion: Tong Zhu's contributions in the realm of drug-conjugates have established him as a leading figure in pharmaceutical innovation. With a robust patent portfolio and a track record of collaboration, Zhu continues to impact the future of targeted drug therapies significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile